Johnson & Johnson is committing up to $60 million for global rights to a Nanobiotix therapy that enhances radiation treatment for head and neck cancer. A Phase 3 test of the nanoparticle-based therapy is expected to yield preliminary data in 2024.
The studies - in lung and head and neck cancers - produced negative results late last year. Several Phase I Imfinzi and tremelimumab studies were also removed, but others were added to the company's pipeline.
3D medical animation services have emerged as a groundbreaking tool in the healthcare industry, revolutionizing the way medical concepts are taught, understood, and marketed.
Results of the Phase III EAGLE study leave Merck's Keytruda and Bristol's Opdivo as the dominant players in the space of HNSCC after progression on platinum-based chemotherapy.
The company plans to use the money for a registrational Phase III study of its severe oral mucositis drug, which showed positive results in Phase IIb trial data presented in June.